(a)    Schedule IV consists of each controlled dangerous substance:

(1)    listed in this section;

(2)    added to Schedule IV by the Department under § 5–202(b) of this title; or

(3)    designated as a Schedule IV controlled dangerous substance by the federal government unless the Department objects under § 5–202(f) of this title.

(b)    Substances listed in Schedule IV include a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

(1)    alfaxalone;

(2)    alprazolam;

(3)    barbital;

(4)    bromazepam;

(5)    butorphanol;

(6)    camazepam;

(7)    carisoprodol;

(8)    cathine +/– (norpseudoepedrine);

(9)    chloral betaine;

(10)    chloral hydrate;

(11)    chlordiazepoxide;

(12)    clobazam;

(13)    clonazepam;

(14)    clorazepate;

(15)    clotiazepam;

(16)    cloxazolam;

(17)    delorazepam;

(18)    dexfenfluramine;

(19)    dextropropoxyphene dosage forms;

(20)    diazepam;

(21)    dichloralphenazone;

(22)    eluxadoline (viberzi);

(23)    estazolam;

(24)    ethchlorvynol;

(25)    ethinamate;

(26)    ethylloflazepate;

(27)    fencamfamin;

(28)    fenproporex;

(29)    fludiazepam;

(30)    flunitrazepam;

(31)    flurazepam;

(32)    halazepam;

(33)    haloxazolam;

(34)    ketazolam;

(35)    loprazolam;

(36)    lorazepam;

(37)    lormetazepam;

(38)    mebutamate;

(39)    medazepam;

(40)    mefenorex;

(41)    methohexital;

(42)    meprobamate;

(43)    methylphenobarbital;

(44)    midazolam;

(45)    modafinil;

(46)    nimetazepam;

(47)    nitrozepam;

(48)    nordiazepam;

(49)    oxazepam;

(50)    oxazolam;

(51)    paraldehyde;

(52)    petrichloral;

(53)    phenobarbital;

(54)    pinazepam;

(55)    pipradrol;

(56)    prazepam;

(57)    quazepam;

(58)    sibutramine;

(59)    SPA (lefetamine);

(60)    suvorexant (belsomra);

(61)    temazepam;

(62)    tetrazepam;

(63)    tramadol;

(64)    triazolam;

(65)    zaleplon (sonata);

(66)    zolpidem (ambien); and

(67)    zopiclone (lunesta).

(c)    Substances listed in Schedule IV include:

(1)    a material, compound, mixture, or preparation that contains fenfluramine; and

(2)    if its existence is possible:

(i)    a salt of fenfluramine;

(ii)    an optical, position, or geometric isomer of fenfluramine; and

(iii)    a salt of an isomer of fenfluramine.

(d)    Substances listed in Schedule IV include a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:

(1)    diethylpropion;

(2)    pemoline, including organometallic complexes and their chelates; and

(3)    phentermine.

(e)    By regulation, the Department may exempt from this section a compound, mixture, or preparation that contains a depressant substance listed in subsection (b) of this section if:

(1)    the compound, mixture, or preparation contains an active medicinal ingredient that does not have a depressant effect on the central nervous system; and

(2)    the admixtures are included in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances that have a depressant effect on the central nervous system.

(f)    The Department may not add a substance to Schedule IV under § 5–202 of this title unless the Department finds that:

(1)    the substance has a low potential for abuse relative to the substances listed in Schedule III;

(2)    the substance has currently accepted medical use in treatment in the United States; and

(3)    abuse of the substance may lead to limited physical dependence or psychological dependence relative to the substances in Schedule III.